ARESTIN’s 25-Year Milestone Highlights Bausch Health’s Leadership in Periodontal Care
Only FDA-Approved Local Antibiotic for Gum Disease Celebrates Quarter-Century of Clinical Use
Bausch Health’s dental division, OraPharma, announced a significant milestone: 25 years since the launch of ARESTIN (minocycline HCl) Microspheres, the only FDA-approved locally applied antibiotic designed to assist dental professionals in treating adult periodontitis. With more than two decades of clinical backing, ARESTIN remains the leading adjunct to scaling and root planing (SRP), a standard treatment for gum disease that affects over one billion people globally.
Impact: ARESTIN Bridges a Key Treatment Gap in Periodontal Care
Periodontal disease, a chronic bacterial infection, often leaves clinicians searching for more targeted, effective treatments. ARESTIN, formulated as tiny, biodegradable microspheres, delivers the antibiotic directly to the periodontal pocket, ensuring sustained release and localized action. Dan Wu, Ph.D., of Bausch Health, emphasized that this innovation fulfilled a critical need, enabling dental professionals to better manage an often under-addressed condition.
Industry Insight: Sustained Safety and Practice Integration
As the only product of its kind approved by the FDA for use alongside SRP, ARESTIN’s legacy is supported by a consistently strong safety profile and ongoing use by dental professionals. Many leading dental practices incorporate ARESTIN as part of comprehensive periodontal management, a testament to its value over 25 years of real-world application.
Strategic Expansion Broadens Access in Underserved Regions
OraPharma has recently moved to expand ARESTIN's availability to Canada and Puerto Rico, aiming to improve access to effective periodontal treatments in markets with unmet dental health needs. This step signals Bausch Health’s commitment to broadening its impact beyond the U.S. and supporting dental communities globally.
Safety and Patient Considerations Remain a Priority
While ARESTIN represents a major advancement, patient selection and awareness remain central. The company advises clinicians and patients to consider key safety information—such as contraindications with certain allergies, pregnancy, or specific health conditions. For example, ARESTIN should not be used in children or during pregnancy due to risk of tooth discoloration, and patients should be aware of potential reactions or increased sensitivity to sunlight.
| Product | Indication | Years Approved | FDA Status | Geographic Expansion (2025-2026) |
|---|---|---|---|---|
| ARESTIN (minocycline HCl) Microspheres | Adjunct to SRP for adult periodontitis | 25 | FDA-Approved | Canada, Puerto Rico |
Looking Forward: Continuing Leadership in Innovation and Collaboration
Tom Stern, head of OraPharma, highlighted that celebrating ARESTIN’s milestone is as much about its legacy as its future. Bausch Health plans to deepen ties with the dental community, drive greater innovation in non-surgical treatments, and extend access to more patients.
Takeaway: Market Signals Underline Steadfast Industry Position
With global periodontal disease prevalence remaining high and access to targeted therapies an ongoing need, ARESTIN’s 25th anniversary underscores Bausch Health’s sustained role in periodontal innovation. Investors, dental professionals, and patients alike may view this milestone as both a reflection of past impact and a signal of continued growth potential in specialized oral care solutions.
Contact Information:
If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.
About the Publisher - Marketchameleon.com:
Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.
NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.
The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.
Disclosure: This article was generated with the assistance of AI